| Cash Flow | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Net loss | -1,380 | -2,544 | -8,985 |
| Stock-based compensation | 0 | 467 | 4,725 |
| Prepaid expenses and other current assets | -152 | 395 | - |
| Accounts payable | -167 | 380 | 398 |
| Due to related party | -2 | 7 | -39 |
| Accrued expenses related party | 28 | 22 | 23 |
| Accrued expenses and other current liabilities | - | - | -66 |
| Net cash flows used in operating activities | -1,369 | -2,063 | -3,944 |
| Payments related to issuance of common stock | - | - | 27 |
| Proceeds from issuance of common stock | 9,831 | - | 4,493 |
| Net cash flows provided by financing activities | 9,831 | - | 4,466 |
| Net increase (decrease) in cash and cash equivalents | 8,462 | -2,063 | 522 |
| Cash and cash equivalents, beginning | 3,080 | 5,143 | 4,621 |
| Cash and cash equivalents, ending | 11,542 | 3,080 | 5,143 |
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)